The Impact of Trump’s 100% Tariff on Indian Pharma: Limited at Best
 Market Reaction vs. Ground Reality  The announcement of a 100% US tariff on branded and patented drug imports , effective October 1, 2025 , triggered a sharp decline in some of India’s biggest pharmaceutical stocks such as Sun Pharma, Dr. Reddy’s Laboratories, and Cipla . However, the market reaction appears largely unfounded.  The tariffs primarily target branded, patented drugs  rather than generic medicines , which form the bulk of India’s exports to the United States. According to ICICI Securities’ research analyst Pankaj Pandey, the near-term impact remains limited , though uncertainty lingers over whether complex generics and biosimilars  might eventually come under the tariff umbrella.   India’s Share in US Pharma Imports  While the US is the largest export market for Indian drugmakers, India accounts for only 5.3% of total US pharma imports .    India’s pharma exports to the US in 2024: $13.1 billion  (about one-third of total pharma exports in FY25).    Ireland was the top ex...